PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21866663-3 2011 The effects of Hp on COX-2 mRNA and protein expressions in human gastric cancer cell line MKN 45 were observed using blocking p38MAPK signal transduction pathway by p38MAPK specific inhibitor SB203580. SB 203580 192-200 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 25451977-7 2015 In both gestational tissues, MEK1/2 (U0126; 10 microM) or p38 inhibition (SB203580; 10 microM) suppressed OT-induced COX-2 expression, but OT-induced p65-phosphorylation was only inhibited in amnion, suggesting OT activation of NF-kappaB in amnion is MAPK-dependent. SB 203580 74-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 30818884-13 2019 The p38 inhibitor SB203580 and the JNK inhibitor SP600125 suppressed MMP-9 and COX-2 expression in H2O2-treated HaCaT cells. SB 203580 18-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 21470077-6 2011 COX-2 expression was markedly suppressed by treatment with the p38 inhibitor, SB203580, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126. SB 203580 78-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 19656660-12 2009 Distinctly, pharmacological inhibition of p38 MAPK with SB203580 was associated with transcriptional down-regulation of COX-2 and MMP-13 in the IL-1beta- or PMA-treated HSF cells. SB 203580 56-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 120-125 20590617-10 2010 Birb 796 and CBS-3868 showed a higher efficacy than SB203580 and pamapimod at inhibiting the expression of COX-2 and MMP13 genes, as well as PGE(2) release. SB 203580 52-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-112 20600219-10 2010 The protein kinase inhibitors had minimal or no effects on Ni/MALP-2-induced accumulation of HIF-1alpha protein, however, COX-2 expression and, more markedly PGE(2) production, were suppressed by LY294002, SB203580, and U0126. SB 203580 206-214 mitochondrially encoded cytochrome c oxidase II Homo sapiens 122-127 12016133-8 2002 Addition of SB-203580 with Ad.dom.neg.IkappaB almost completely blocked carbachol stimulation of COX-2 gene expression. SB 203580 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 16926398-7 2006 R. rickettsii-induced COX-2 was sensitive to inhibitors of de novo transcription and the pyridinylimidazole-based compound SB 203580, suggesting that this transcriptional host cell response involves signaling through p38 mitogen-activated protein kinase. SB 203580 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 16423197-5 2006 SB203580 and H-7, but not PD098059, inhibited IL-1beta-induced expression of COX-2 protein. SB 203580 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 15319438-7 2004 pp38 MAPK inhibitor SB203580 or eIF2alpha phosphorylation inhibitor 2-aminopurine attenuated the nuclear NF-kappaB DNA binding activity and COX-2 induction. SB 203580 20-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 140-145 14764449-7 2004 Western blot analysis revealed that SB-203580 inhibited upregulation of COX-2 that was observed in untreated ischemic-injured mucosa, whereas PD-98059 had no effect on COX-2 expression. SB 203580 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 12096032-5 2002 PD98059 (MEK1 inhibitor) and SB203580 (p38(MAPK) inhibitor) reduced PGE(2) production as well as COX-2 expression in LPS-stimulated neutrophils. SB 203580 29-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 19084589-7 2009 Importantly, the manganese-induced COX-2 expression was suppressed by treatment with the inhibitor of p38 MAPK (SB203580), PI3K/PKB (LY294002), PKCs (GO6983, GF109203X, Rottlerin), Src (PP1), or the thiol-containing compound (NAC). SB 203580 112-120 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 18842828-8 2008 Both the JNK inhibitor SP600125 and the p38 inhibitor SB203580 prevented the MGO induction of COX-2. SB 203580 54-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 94-99 18287347-11 2008 SB203580 (p38MAPK inhibitor) and U0126 (MAPK kinase1/2 inhibitor) abrogated the upregulation of Cox-2 and PGI2 release induced by oleanolic acid. SB 203580 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 16300728-5 2006 SB203580, a p38 MAPK inhibitor, but not PD098059 and SP600125, specific inhibitor of MKK1 and selective inhibitor of JNK, respectively, suppressed COX-2 expression. SB 203580 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 15657353-7 2005 Selective inhibitors of sulindac sulfide-induced ERKp44/42 (PD98059) and p38 MAPK (SB203580) activation also suppressed the induction of COX-2 by this NSAID. SB 203580 83-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 15298620-12 2004 PD98059 and SB203580 also suppressed serum-induced expression of COX-2 protein in HT29 cells. SB 203580 12-20 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-70 15272234-5 2004 In addition, the induction of COX-2 and MMP-2 was inhibited by the pretreatment of chondrocytes with a SB203580 or Ro 31-8220, indicating the involvement of protein kinase C (PKC) or p38 mitogen-activated protein kinase (MAPK). SB 203580 103-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 14751545-4 2004 TNF-alpha-induced COX-2 expression and PGE2 synthesis were also inhibited by PD98059 (an inhibitor of MEK1/2) and SB203580 and SB202190 (inhibitors of p38 MAPK), respectively, suggesting the involvement of p42/p44 and p38 MAPKs in these responses. SB 203580 114-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 15020231-6 2004 Catalase-induced COX-2 expression was abrogated by treatment of MG-132 (a NF-kappaB inhibitor) or LY294002 (a PI3K inhibitor), but not by treatment of PD98059 (an ERK inhibitor), SB203580 (a p38 inhibitor), or SP600125 (a JNK inhibitor). SB 203580 179-187 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 12237297-8 2002 Co-incubation of the specific p38 inhibitor, SB203580 or PD169316, inhibited a low salt-induced increase in luciferase activity of the intact COX-2 promoter (5.8 +/- 0.7 versus 1.1 +/- 0.2, n = 8 and 1.4 +/- 0.4, n = 4 respectively, p < 0.01). SB 203580 45-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-147 11053030-4 2000 The p38 inhibitor SB-203580 (3 microM) decreased IL-1 beta-induced COX-2 by 70 +/- 7% (P < 0.01). SB 203580 18-27 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 11910351-6 2002 The MAPK inhibitors, PD098059 for MAP or extracellular signal-regulated kinase 1, SB203580 for p38, and BAY 37-9751 for Raf-1, blocked COX-2 induction by bile acids. SB 203580 82-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 135-140 11853544-6 2002 SB203580, a selective p38 mitogen-activated protein kinase (MAPK) inhibitor, completely abolished the IL-1beta-induced COX-2 mRNA. SB 203580 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 119-124 11487528-10 2001 Also, SB203580, the selective inhibitor of p38 MAP kinase, strongly blocked the induction of COX-2 by SIN-1 in the presence or absence of IL-1alpha, whereas the MEK-1 inhibitor, PD 98059, affected it to a lesser extent. SB 203580 6-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-98 11179444-2 2001 TNF-alpha-mediated COX-2 expression and COX-2 promoter activity were inhibited by the MAPK kinase inhibitor PD98059 or the p38 inhibitor SB203580. SB 203580 137-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 11179444-2 2001 TNF-alpha-mediated COX-2 expression and COX-2 promoter activity were inhibited by the MAPK kinase inhibitor PD98059 or the p38 inhibitor SB203580. SB 203580 137-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 11179444-6 2001 SMase- or C2-ceramide-induced COX-2 expression and COX-2 promoter activity were also inhibited by PD98059 or SB203580. SB 203580 109-117 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 11179444-6 2001 SMase- or C2-ceramide-induced COX-2 expression and COX-2 promoter activity were also inhibited by PD98059 or SB203580. SB 203580 109-117 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 9849881-2 1998 SB 203580, an inhibitor of p38 MAPK, in the range 0.1-1 microM inhibited IL-1-stimulated PGE2 (but not arachidonic acid) release and this was associated with inhibition of induction of COX-2 protein and mRNA. SB 203580 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 185-190 10595652-5 1999 Either tyrphostin-47, PD98059, a specific inhibitor of the upstream kinase toward ERK1/2, or SB203580, a specific inhibitor of p38, completely suppressed vanadate-induction of COX-2 mRNA and protein. SB 203580 93-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 176-181 9473245-7 1998 Similarly, an inhibitor of the p38 mitogen-activated protein kinase, SB 203580, inhibited the stimulation of COX-2. SB 203580 69-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-114